Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 2/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.31 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.31 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.31 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.31 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18145665 | 0.80 | NOS1 (0.30) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL29100706 | 0.74 | HDAC3 (0.39) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL29100702 | 0.74 | HDAC3 (0.39) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL18477 | 0.73 | LTA4H (0.43) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL1654337 | 0.73 | LTA4H (0.43) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL1841835 | 0.73 | LTA4H (0.43) | NOS1NOS3NOS2HDAC3HDAC1 | |
| SCHEMBL14454329 | 0.73 | LTA4H (0.35) | NOS1NOS3NOS2 | |
| SCHEMBL18145528 | 0.72 | POLB (0.39) | HDAC1HDAC2HDAC6 | |
| SCHEMBL14729331 | 0.72 | POLB (0.39) | HDAC1HDAC2HDAC6 | |
| Water SCHEMBL3912787 | 0.71 | LTA4H (0.42) | NOS1NOS3NOS2HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11351151-B2 | Compound having anticancer activity and preparation method and application | 3D MEDICINES (BEIJING) CO., LTD. (CN) | 2022-06-07 | — | — | US | disclosed |
| US-20200038371-A1 | COMPOUND HAVING ANTICANCER ACTIVITY AND PREPARATION METHOD AND APPLICATION | 3D MEDICINES (BEIJING) CO., LTD. (CN) | 2020-02-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200038371-A1 | COMPOUND HAVING ANTICANCER ACTIVITY AND PREPARATION METHOD AND APPLICATION | HDGF, MKI67, LITAF | NOS1 1239/4885NOS3 1652/4885NOS2 986/4885 |
| US-11351151-B2 | Compound having anticancer activity and preparation method and application | HDGF, MKI67, LITAF | NOS1 1357/4885NOS3 1657/4885NOS2 965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.